MaxCyte, Inc. (MXCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.28+1.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MXCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -7.8% |
| Our one-year growth estimate | diamond | 14.6% |
Growth built into the price is above our model estimate.
The price assumes 22.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MXCT — legal / regulatory event
Dated 2026-06-16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading…
Why it matters: Meeting this revenue target supports the company's guidance for the full year. It shows growth momentum in core business.
Supportive ifQ2 2026 total revenue reported at or above $10 million.
Worry ifQ2 2026 total revenue was less than $10 million.
Why it matters: Following Nasdaq listing rules is key. It helps keep market access and investor trust.
Worry ifThe stock price has stayed above $1.00 for 10 days in a row.
Less concerning ifNasdaq sent a notice about ongoing issues with the $1.00 bid price rule.
Why it matters: A drop below this level would signal trouble in meeting 2026 revenue guidance.
Worry ifIf Q2 revenue is below $7 million, it shows big weakness.
Less concerning ifQ2 revenue above $7 million would show stronger performance and support guidance.
Why it matters: Meeting this target is key to achieving the full year revenue guidance of $30-32 million.
Supportive ifQ3 total revenue is $7.5 million or more. This shows progress for the year.
Worry ifQ3 total revenue is less than $7.5 million. This raises concerns for the year.
Why it matters: Updates on meeting the minimum bid price could affect the stock listing.
Watch forA good update shows compliance with Nasdaq's minimum bid price requirement.
Also watch forA bad update that leads to delisting shows serious problems.
Why it matters: New trials would validate the strategic platform and could lead to increased revenue.
Supportive ifAt least one new SPL customer is starting a trial.
Worry ifNo new SPL customers are starting trials.
Why it matters: Updates on Nasdaq compliance will show if MaxCyte can meet listing rules.
Worry ifA press release says MaxCyte meets Nasdaq's minimum bid price rule.
Less concerning ifThere are more notices of non-compliance or delisting threats from Nasdaq.
Why it matters: The share buyback program shows that management wants to give value back to shareholders.
Supportive ifManagement says over $7 million of the share buyback program has been completed.
Worry ifNo updates on the share repurchase program or a slowdown in repurchases.
Why it matters: A larger decline in core revenue would signal ongoing issues in MaxCyte's business. It would raise concerns about the company's growth strategy.
Worry ifCore revenue for Q3 2026 is down year over year worse than -20%.
Less concerning ifCore revenue for Q3 2026 is flat or grows year over year.
Why it matters: More SPL revenue shows strong partnerships and growth for MaxCyte. This can boost investor trust.
Supportive ifSPL Program revenue for Q3 2026 is over $1 million.
Worry ifSPL Program-related revenue for Q3 2026 is below $0.8 million.
Why it matters: A drop below this threshold could indicate cash flow issues and impact future growth plans. It would raise concerns about financial stability.
Worry ifTotal cash, cash equivalents, and investments fall below $130.5 million by end of 2026.
Less concerning ifTotal cash, cash equivalents, and investments remain above $130.5 million by end of 2026.
Why it matters: Good news from this partnership can prove MaxCyte's technology. It may create new income.
Supportive ifNews about successful goals or income from the Genentech partnership.
Worry ifNo news or bad updates about the Genentech partnership.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $704 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,305 loss on $10,000 · 63.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.